Featured Research

from universities, journals, and other organizations

Minorities face barriers to effective ADHD treatments, study contends

Date:
May 12, 2010
Source:
Michigan State University
Summary:
Several barriers prevent minority children with ADHD from receiving the most effective treatments, according to a new study.

Several barriers prevent minority children with ADHD from receiving the most effective treatments, according to a new study by Michigan State University researchers.

In the May issue of the Journal of Attention Disorders, the researchers argue schools and communities should do a better job of getting information to minority families about the combined benefit of medication and counseling for attention deficit hyperactivity disorder.

"ADHD has multiple causes and multiple treatment approaches are warranted," said John Carlson, associate professor of school psychology. Carlson co-authored the study with Andy Pham, a recent Ph.D. graduate, and John Kosciulek, professor of rehabilitation counseling.

More than 4.5 million children have been diagnosed with ADHD in the United States, making it one of the most common childhood disorders, according to the Centers for Disease Control and Prevention.

The disorder, characterized by impulsive behavior and inattentiveness, often lasts into adulthood. Causes include both biological and environmental factors, the study said.

Medication such as Ritalin has shown to decrease hyperactivity in children with ADHD, while counseling such as behavior therapy and parent training can lead to improved relationships with family and friends, Carlson said. The treatments can be successfully combined to treat severe behavioral problems, he said.

But according to study, which included a scientific survey of parents, blacks and Latinos are less likely than whites to consider combining medication and counseling for their children. The barriers preventing minorities from seeking and using these treatments include a lack of culturally competent health-care providers, financial hurdles and little dissemination of information about treatments that work.

Pham said the "significant increase in children diagnosed with ADHD" intensifies the need for parents to be informed of all treatment options.

"Parents may bring different cultural beliefs to the treatment context," Pham said. "Therefore practitioners such as physicians and school psychologists must build on their own cultural knowledge when working with families to determine the best course of action."


Story Source:

The above story is based on materials provided by Michigan State University. Note: Materials may be edited for content and length.


Journal Reference:

  1. A. V. Pham, J. S. Carlson, J. F. Kosciulek. Ethnic Differences in Parental Beliefs of Attention-Deficit/Hyperactivity Disorder and Treatment. Journal of Attention Disorders, 2009; 13 (6): 584 DOI: 10.1177/1087054709332391

Cite This Page:

Michigan State University. "Minorities face barriers to effective ADHD treatments, study contends." ScienceDaily. ScienceDaily, 12 May 2010. <www.sciencedaily.com/releases/2010/05/100512131517.htm>.
Michigan State University. (2010, May 12). Minorities face barriers to effective ADHD treatments, study contends. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/05/100512131517.htm
Michigan State University. "Minorities face barriers to effective ADHD treatments, study contends." ScienceDaily. www.sciencedaily.com/releases/2010/05/100512131517.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins